Bulevirtide and tenofovir combination therapy for hepatitis D virus infection: longer treatment and more diverse trial populations are needed. The Lancet. Infectious diseases Ito, T., Nguyen, M. H. 2022

View details for DOI 10.1016/S1473-3099(22)00412-1

View details for PubMedID 36113539